These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 22141608)

  • 1. Early post-treatment pseudo-progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: a retrospective analysis.
    Gunjur A; Lau E; Taouk Y; Ryan G
    J Med Imaging Radiat Oncol; 2011 Dec; 55(6):603-10. PubMed ID: 22141608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide.
    Sherriff J; Tamangani J; Senthil L; Cruickshank G; Spooner D; Jones B; Brookes C; Sanghera P
    Br J Radiol; 2013 Feb; 86(1022):20120414. PubMed ID: 23385995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isocitrate dehydrogenase 1 mutant glioblastomas demonstrate a decreased rate of pseudoprogression: a multi-institutional experience.
    Mohammadi H; Shiue K; Grass GD; Verma V; Engellandt K; Daubner D; Schackert G; Gondim MJ; Gondim D; Vortmeyer AO; Kamer AP; Jin W; Robinson TJ; Watson G; Yu HM; Lautenschlaeger T
    Neurooncol Pract; 2020 Mar; 7(2):185-195. PubMed ID: 32626587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM.
    Rowe LS; Butman JA; Mackey M; Shih JH; Cooley-Zgela T; Ning H; Gilbert MR; Smart DK; Camphausen K; Krauze AV
    J Neurooncol; 2018 Aug; 139(1):145-152. PubMed ID: 29767308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of boost sequence in concurrent chemo-radiotherapy on newly diagnosed IDH-wildtype glioblastoma multiforme.
    Kim N; Lee J; Nam DH; Lee JI; Seol HJ; Kong DS; Choi JW; Chong K; Lee WJ; Chang JH; Kang SG; Moon JH; Cho J; Lim DH; Yoon HI
    J Neurooncol; 2023 Nov; 165(2):261-268. PubMed ID: 37861921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early pseudoprogression and progression lesions in glioblastoma patients are both metabolically heterogeneous.
    Ungan G; Pons-Escoda A; Ulinic D; Arús C; Ortega-Martorell S; Olier I; Vellido A; Majós C; Julià-Sapé M
    NMR Biomed; 2024 Apr; 37(4):e5095. PubMed ID: 38213096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of Pseudoprogression versus Progression using Machine Learning Algorithm in Glioblastoma.
    Jang BS; Jeon SH; Kim IH; Kim IA
    Sci Rep; 2018 Aug; 8(1):12516. PubMed ID: 30131513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response assessment of GBM during immunotherapy by delayed contrast treatment response assessment maps.
    Cuccarini V; Savoldi F; Mardor Y; Last D; Pellegatta S; Mazzi F; Bruzzone MG; Anghileri E; Pollo B; Maddaloni L; Russo C; Bocchi E; Pinzi V; Eoli M; Aquino D
    Front Neurol; 2024; 15():1374737. PubMed ID: 38651109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pseudoprogression in glioblastoma patients: the impact of extent of resection.
    Park HH; Roh TH; Kang SG; Kim EH; Hong CK; Kim SH; Ahn SS; Lee SK; Choi HJ; Cho J; Kim SH; Lee KS; Suh CO; Chang JH
    J Neurooncol; 2016 Feb; 126(3):559-66. PubMed ID: 26608521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and outcome of pseudoprogression after radiation therapy in glioblastoma patients: A cohort study.
    Blakstad H; Mendoza Mireles EE; Heggebø LC; Magelssen H; Sprauten M; Johannesen TB; Vik-Mo EO; Leske H; Niehusmann P; Skogen K; Helseth E; Emblem KE; Brandal P
    Neurooncol Pract; 2024 Feb; 11(1):36-45. PubMed ID: 38222046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of treatment response to dendritic cell vaccine in patients with glioblastoma using a multiparametric MRI-based prediction model.
    de Godoy LL; Chawla S; Brem S; Wang S; O'Rourke DM; Nasrallah MP; Desai A; Loevner LA; Liau LM; Mohan S
    J Neurooncol; 2023 May; 163(1):173-183. PubMed ID: 37129737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI-based contrast clearance analysis shows high differentiation accuracy between radiation-induced reactions and progressive disease after cranial radiotherapy.
    Bodensohn R; Forbrig R; Quach S; Reis J; Boulesteix AL; Mansmann U; Hadi I; Fleischmann DF; Mücke J; Holzgreve A; Albert NL; Ruf V; Dorostkar M; Corradini S; Herms J; Belka C; Thon N; Niyazi M
    ESMO Open; 2022 Apr; 7(2):100424. PubMed ID: 35248822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of neurotoxicities associated with immunotherapy and a framework for evaluation.
    Burton LB; Eskian M; Guidon AC; Reynolds KL
    Neurooncol Adv; 2021 Nov; 3(Suppl 5):v108-v120. PubMed ID: 34859238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pseudoprogression and Immunotherapy Phenomena.
    Waxman ES; Lee Gerber D
    J Adv Pract Oncol; 2020; 11(7):723-731. PubMed ID: 33575068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinguishing Extravascular from Intravascular Ferumoxytol Pools within the Brain: Proof of Concept in Patients with Treated Glioblastoma.
    Barajas RF; Schwartz D; McConnell HL; Kersch CN; Li X; Hamilton BE; Starkey J; Pettersson DR; Nickerson JP; Pollock JM; Fu RF; Horvath A; Szidonya L; Varallyay CG; Jaboin JJ; Raslan AM; Dogan A; Cetas JS; Ciporen J; Han SJ; Ambady P; Muldoon LL; Woltjer R; Rooney WD; Neuwelt EA
    AJNR Am J Neuroradiol; 2020 Jul; 41(7):1193-1200. PubMed ID: 32527840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value.
    Hwang I; Choi SH; Park CK; Kim TM; Park SH; Won JK; Kim IH; Lee ST; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
    AJNR Am J Neuroradiol; 2020 Jan; 41(1):49-56. PubMed ID: 31806595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended Volumetric Follow-up of Juvenile Pilocytic Astrocytomas Treated with Proton Beam Therapy.
    Mannina EM; Bartlett GK; McMullen KP
    Int J Part Ther; 2016; 3(2):291-299. PubMed ID: 31772980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased risk of pseudoprogression among pediatric low-grade glioma patients treated with proton versus photon radiotherapy.
    Ludmir EB; Mahajan A; Paulino AC; Jones JY; Ketonen LM; Su JM; Grosshans DR; McAleer MF; McGovern SL; Lassen-Ramshad YA; Adesina AM; Dauser RC; Weinberg JS; Chintagumpala MM
    Neuro Oncol; 2019 May; 21(5):686-695. PubMed ID: 30753704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide.
    Dworkin M; Mehan W; Niemierko A; Kamran SC; Lamba N; Dietrich J; Martinez-Lage M; Oh KS; Batchelor TT; Wen PY; Loeffler JS; Shih HA
    J Neurooncol; 2019 Mar; 142(1):69-77. PubMed ID: 30488294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.